Acura Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Acura Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Acura Pharmaceuticals Inc Strategy Report
- Understand Acura Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops and commercializes products and technologies to prevent the abuse and misuse of medication. Acura’s proprietary technologies include, Aversion, Limitx, and Impede technology. The company’s Limitx technology helps to minimize the risks associated with drug overdose and Aversion technology is to address methods of abuse associated with opioid analgesics. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.
Headquarters
United States of America
Address
616 N North Ct Ste 120, Palatine, Illinois, 60067-8121
Website
acurapharm.com
Telephone
1 847 7057709
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACUR (OTC)
Revenue (2021)
$1.6M
-56.2%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
27.2%
(2021 vs 2020)
Market Cap*
$660,000
Net Profit Margin (2021)
XYZ
-66.2%
(2021 vs 2020)
* As of and is in US$
Acura Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Oxaydo |
| Oxaydo (oxycodone HCl) Tablets- Acute and Chronic Moderate to Severe Pain | Aversion |
| Nexafed 30mg | Nexafed |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Acura Pharmaceuticals Inc | Pfizer Inc | Collegium Pharmaceutical Inc | Ensysce Biosciences Inc | AcelRx Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Palatine | New York | Stoughton | La Jolla | San Mateo |
| State/Province | Illinois | New York | Massachusetts | California | California |
| No. of Employees | 14 | 83,000 | 207 | 7 | 19 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert B. Jones | President; Chief Executive Officer; Director | Executive Board | 2011 | 64 |
| Peter A. Clemens | Chief Financial Officer; Senior Vice President; Secretary | Senior Management | 2004 | 70 |
| John G. Gilkay | Director - EHS and Engineering | Senior Management | 2004 | - |
| James F. Emigh | Vice President - Corporate Development | Senior Management | 2011 | 65 |
| Albert W. Brzeczko, Ph.D. | Vice President - Pharmaceutical Sciences | Senior Management | 2019 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer